Jubilant Life Sciences receives ANDA approval for Montelukast

02 Mar 2015 Evaluate

Jubilant Life Sciences, an integrated Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Singulair Chewable Tablets (of Merck), which is used for the treatment of asthma and to relieve symptoms of seasonal allergies. The total market size for Montelukast Tablets as per IMS is $83 Million per annum.

Jubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally, as on December 31, 2014. This includes 72 ANDAs filed in the US, of which 35 have been approved and 46 Dossier filings in Europe. The company has so far received 10 ANDA approvals during FY 2015.

Jubilant Pharmova Share Price

1076.40 7.20 (0.67%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×